Group 1 - The core announcement is regarding the positive interim results from the ongoing Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP) conducted by Dogwood Therapeutics, Inc. [1] - The study involved 97 patients who completed treatment, showing a significant difference in pain improvement between those receiving Halneuron and those on placebo [1]. - The average duration of CINP among the study participants was 5 years, with 67% of patients concurrently on stable doses of other chronic pain medications [2]. Group 2 - The overall dropout rate for the study was approximately 4.4%, which is significantly lower than the dropout rates of other FDA-approved chronic pain medications [2]. - Dogwood anticipates obtaining preliminary results by Q3 2026, based on the current recruitment pace and interim analysis results, with an expected statistical power of 80% to 85% to detect treatment differences [2]. - Dogwood is a development-stage biopharmaceutical company focused on developing new drugs for pain relief and neuropathic symptoms, holding approximately 83% indirect equity interest in Dogwood [2].
长江生命科技：Halneuron 治疗因化疗引致的神经痛症第二b期研究中期分析取得正面结果